You just read:

Data on Merck's Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014

News provided by

Merck Canada Inc.

Jun 02, 2014, 10:02 ET